SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.19 CNY | -0.96% |
|
+2.57% | -10.12% |
| 15/04 | Grifols Plans to Appoint Independent Directors Only to Audit, Compensation Committees | MT |
| 10/04 | Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake | RE |
| Sales 2023 * | 7.8B 1.08B 89.74B | Sales 2024 * | 9.08B 1.25B 104B | Capitalization | 47.78B 6.59B 550B |
|---|---|---|---|---|---|
| Net income 2023 * | 2.17B 300M 25B | Net income 2024 * | 2.52B 348M 29.05B | EV / Sales 2023 * | 6.13 x |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 5.26 x |
| P/E ratio 2023 * |
22.1
x | P/E ratio 2024 * |
18.9
x | Employees | 3,121 |
| Yield 2023 * |
0.51% | Yield 2024 * |
0.56% | Free-Float | 68.13% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | -0.96% | ||
| 1 week | +2.57% | ||
| Current month | +1.27% | ||
| 1 month | +2.42% | ||
| 3 months | +5.12% | ||
| 6 months | +4.81% | ||
| Current year | -10.12% |
1 week
6.96
7.32
1 month
6.667.32
Current year
5.938.60
1 year
5.938.68
3 years
4.988.68
5 years
4.9811.16
10 years
4.9826.67
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Xu
CEO | Chief Executive Officer | 60 | 01/12/01 |
Le Qi Chen
DFI | Director of Finance/CFO | 37 | 26/21/26 |
Wei Bing Hu
CHM | Chairman | 60 | 03/03/03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 20/20/20 | |
Yue Wen Zheng
BRD | Director/Board Member | 62 | 27/07/27 |
David Ian Bell
BRD | Director/Board Member | 70 | 20/20/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.71% | 2 M€ | -14.14% | ||
| 0.69% | 2 M€ | -16.59% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 7.19 | -0.96% | 32,985,570 |
| 25/24/25 | 7.26 | +2.69% | 44,895,570 |
| 24/24/24 | 7.07 | +0.43% | 23,964,500 |
| 23/24/23 | 7.04 | -0.28% | 26,719,940 |
| 22/24/22 | 7.06 | +0.71% | 27,407,080 |
End-of-day quote Shenzhen S.E., April 26, 2024
More quotes
Shanghai RAAS Blood Products Co., Ltd. specializes in the research, development and manufacturing of plasma-derived therapeutics. The group's products include human albumin, immunoglobulin and coagulation factors (thrombin, fibrinogen, prothrombin and fibrin).
China accounts for 96.6% of net sales.
Sector
Pharmaceuticals
Calendar
30/04/2024
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.19
CNY
Average target price
7
CNY
Spread / Average Target
-2.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.12% | 6.59B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 002252 Stock
